Format

Send to

Choose Destination
Lung Cancer. 2008 Nov;62(2):253-60. doi: 10.1016/j.lungcan.2008.03.003. Epub 2008 Apr 15.

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.

Author information

1
Institute of Clinical Medicine, University of Tromsø and Department of Oncology, University Hospital of Northern Norway, Norway. nina.helbekkmo@fagmed.uit.no

Abstract

BACKGROUND:

There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.

PATIENTS AND METHODS:

The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.

RESULTS:

PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.

CONCLUSIONS:

Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.

PMID:
18417246
DOI:
10.1016/j.lungcan.2008.03.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center